Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes

John Mascarenhas, Claire Harrison, Tammy A. Schuler, Djibril Liassou, Marné Garretson, Taavy A. Miller, Sankar Mahadevan, Ali McBride, Derek Tang, Irene S. DeGutis, Pranav Abraham, Jonathan Kish, Bruce A. Feinberg, Aaron T. Gerds

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: There is a lack of established clinical outcomes for patients with myelofibrosis (MF) receiving fedratinib following ruxolitinib failure. This study examined real-world patient characteristics, treatment patterns, and clinical outcomes of patients with MF treated with fedratinib following ruxolitinib failure in US clinical practice. Patients and Methods: This retrospective patient chart review included adults with a physician-reported diagnosis of MF, who initiated fedratinib after discontinuing ruxolitinib. Descriptive analyses characterized patient characteristics, clinical outcomes, and treatment patterns from MF diagnosis through ruxolitinib and fedratinib treatment. Results: Twenty-four physicians abstracted data for 150 eligible patients. Approximately 55.3% of the patients were male, 68.0% were White, and median age at MF diagnosis was 68 (range, 35-84) years. Median duration of ruxolitinib therapy was 7.6 (range, 0.7-65.5) months. At initiation of fedratinib, 88.0% of patients had palpable spleen and a mean spleen size of 16.0 (standard deviation [SD], 5.9) cm. Spleen size decreased by 19.4% to 13.2 (SD, 7.9) cm at month 3 (P = .0001) and by 53.4% to 7.2 (SD, 7.4) cm at month 6 (P = .01) of fedratinib treatment, respectively. Almost one-third (26.8%) of patients had achieved ≥ 50% spleen reduction by month 6. Mean number of symptoms also decreased significantly at month 3 (P < .0001) and month 6 (P = .01). Conclusion: Fedratinib appears to deliver spleen and symptom benefits in real-world patients with MF previously treated with ruxolitinib.

Original languageEnglish
Pages (from-to)122-132
Number of pages11
JournalClinical Lymphoma, Myeloma and Leukemia
Volume24
Issue number2
DOIs
StatePublished - Feb 2024

Keywords

  • Janus kinase 2 inhibitor
  • Myeloproliferative neoplasms
  • Real-world data

Fingerprint

Dive into the research topics of 'Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes'. Together they form a unique fingerprint.

Cite this